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Statin-induced Myopathy
ATHEROSCLEROTIC 
CARDIOVASCULAR 
DISEASE
statin use. In order of decreasing frequency and increasing 
severity they are: 
 ■ Asymptomatic elevation in serum creatine kinase (CK) 
level,
 ■ myalgia (without elevation in the CK), 
 ■ myositis (with an elevated CK) and 
 ■ rhabdomyolysis.(6) 
Rhabdomyolysis is defined as muscle symptoms associated with 
a marked elevation in CK (typically much in excess of 10X 
normal) and an elevation in serum creatinine and myoglobinuria. 
It is rarely encountered with statin monotherapy.(7) An excess 
of rhabdomyolysis of 0.01% vs. placebo was reported in trials.(8) 
Death from rhabdomyolysis with statin therapy has been 
encountered in <1 in a million prescriptions.(7) Notwithstanding, 
unless recognised and treated early, rhabdomyolysis carries a 
dire prognosis and must be excluded promptly when patients 
on statins present with muscle pain. 
In addition to the above, a very rare condition, necrotising 
immune-mediated statin myopathy (IMSM), has been recognised 
recently.(9) This appears to be a genetically mediated, auto-
immune reaction caused or unmasked by statin therapy. IMSM 
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INTRODUCTION
Dyslipidaemia is a major risk factor for the development of 
atherosclerotic cardiovascular disease, the most frequent cause 
of death worldwide. A large number of trials have demon-
strated that reducing LDL cholesterol with 3-hydroxy-3-
methyl-glutaryl-CoA (HMGCoA) reductase inhibitors (com-
monly known as statins) is both safe and effective in decreasing 
the risk of myocardial infarction, stroke and death. These 
findings have been collated by the Cholesterol Trialists’ Colla-
boration(1) and both local(2) and international(3,4) guidelines on 
cardiovascular prevention have incorporated recommenda-
tions supporting the use of statin therapy in primary and 
secondary prevention. Broadly, these guidelines support the 
concept of “lower is better” and recommend high dose po-
tent statin treatment(4) for patients with established disease, 
patient with diabetes, and those with a very high risk of 
developing cardiovascular disease, aiming to achieve levels of 
LDL cholesterol <1.8 mmol/L.(2,3) Moderate doses of statin are 
recommended for those at less than very high risk. A significant 
uptake of this advice by the medical community has resulted in 
the widespread prescription of statins.
STATIN ASSOCIATED MYOPATHY
The occurrence of myalgia without CK elevation during statin 
therapy was not widely appreciated before 2002.(5) However, 
two thirds of the side-effects of statin treatment arise from 
muscle symptoms.(6) The term statin-associated myopathy is 
used here to encompass all muscle problems that arise during 
Atherosclerotic cardiovascular disease (ASCVD) is the 
leading cause of death worldwide.  HMGCoA reductase 
inhibitors or “statins” reduce low density lipoprotein 
cholesterol and reduce the risks of myocardial infarc-
tion, stroke and death in the presence of dyslipidaemia. 
In consequence, statins are prescribed to a large number 
of patients requiring primary or secondary prevention. 
A variety of side-effects may arise during the course of 
statin treatment which interfere with the quality of 
patients’ lives and reduce their compliance with therapy. 
Muscle symptoms constitute the most common of 
these side-effects and are the most frequent reason for 
discontinuing treatment. This review defi nes the muscle, 
tendon and joint disorders encountered by patients on 
statin treatment, their possible relationship to statin 
use, and the factors that facilitate the emergence of 
symptoms. The subtypes of statin myopathy are 
discussed and a general defi nition of statin myopathy is 
offered. Expert advice on managing statin myopathy is 
summarised.  SAHeart 2015;12:14-18
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is characterised by persistent or worsening symptoms despite 
the withdrawal of treatment, elevation in CK, and dependence 
upon immunosuppressive therapy to prevent relapse. 
The mechanism/s by which statins induce these changes in 
skeletal muscle are not fully understood. Drug interactions, 
genetic predisposition, depletion of metabolites in the meva-
lonate pathway, mitochondrial dysfunction, dysregulation of 
apoptosis and protein degradation and immune mechanisms 
have all been implicated.(10)
The muscle ache and/or muscle weakness associated with a 
statin myopathy is most often bilateral, but may be asymmetrical. 
It predominantly affects large muscle groups around the 
shoulders, hips, thighs and/or calves. Although the patient 
cannot usually identify a precipitating factor, recent strenuous 
or unaccustomed exercise, or an alteration in medication may 
be reported.(10) There are no specific clinical signs that 
accompany the pain. The serum CK should be measured and 
may be elevated.
While the patient’s symptoms may be tolerable and not 
necessarily severe, statin myopathy reduces adherence to 
treatment, limits physical activity, reduces the quality of life, and 
may lead to discontinuation of statin therapy, ultimately 
depriving the at-risk dyslipidaemic patient of the clinical benefits 
of statin treatment.(8)
The incidence of muscle aches (myalgia), muscle cramps(11) 
and weakness is generally reported to be in the region of 
7-11% of patients taking statin monotherapy(8) but is encoun-
tered more frequently when drugs that interact with statins are 
given concomitantly, or in the presence of certain co-morbid 
conditions. However, there is no consensus on the frequency 
at which statin myopathy occurs. The observed incidence of 
muscle symptoms is greater in clinical practice than was noted 
in clinical trials. This discrepancy may arise from the non-specific 
nature of the symptoms, the lack of a clear definition of statin 
myopathy, or from the design of some clinical trials which 
excluded patients who developed muscle symptoms during a 
run-in period or did not specifically require the solicitation of 
muscle problems.(12) Because many patients requiring statin 
treatment are middle aged, it may be difficult to establish 
whether their symptoms are caused by the statin therapy or 
originate from unrelated musculoskeletal conditions. Although 
placebo controlled clinical trials have recorded a higher rate of 
myalgia in patients treated with statins, the placebo groups in 
these trials had nearly as many muscle symptoms as the actively 
treated groups. An extensive review of published trials 
concluded that both patients and physicians overestimate the 
frequency of myalgia associated with statins and that muscle 
symptoms are much less common than the 25% incidence 
stated in certain reports.(12)
Myalgia is the most common reason that patients discontinue 
statin treatment. On average, symptoms appear within 4 weeks 
of starting treatment(13,14) but their onset may be delayed for 
up to 2 years.(15) The frequency of statin myopathy does not 
increase with longer term treatment.(16) The reported incidence 
of muscle symptoms in statin trials suggests that the frequency 
of symptoms relates to the potency of the statin employed.(12) 
There may be a relationship between the incidence of statin-
associated myopathy and the extent of reduction in total and 
LDL cholesterol(17) although this is not supported by the 
results of clinical trials or clinical experience.(18)
There is no standard definition of statin myopathy nor is there 
any test that conclusively proves the diagnosis. The STOMP 
trial defined statin-associated myalgia as new or increased 
muscle pain, cramps, or aching unassociated with exercise that 
persisted for 2 weeks and resolved within 2 weeks of stopping 
the drug and reoccurred within 4 weeks of restarting the 
medication.(14) STOMP tested atorvastatin 80mg daily vs. 
placebo for 6 months in healthy subjects, demonstrating an 
increase in muscle symptoms (9.4% vs. 4.8%) and a modest rise 
in CK on atorvastatin therapy (about 20 U/L). The rise in CK 
suggested a low level of skeletal muscle injury that was not 
related to the emergence of symptoms. STOMP found that 
muscle strength, endurance or aerobic performance were 
impaired only if the patient fulfilled the criteria for statin-
induced myalgia. 
Statin myopathy arises from complex interactions between the 
specific statin, concurrent disease, genetic predisposition and 
concomitant treatment.(19) Although it is a class effect, the 
incidence of myopathy varies amongst the various members of 
the drug class. Myopathy is seen 4 times more frequently with 
simvastatin 80mg compared to atorvastatin 80mg.(20) Whereas 
simvastatin, atorvastatin and rosuvastatin are more commonly 
associated with statin myopathy, it is rarely found in associa-
tion with the less potent agents viz. fluvastatin or pravastatin(21) 
or pitivastatin.(22) Statin myopathy may be aggravated by 
strenuous exercise and may affect up to 75% of athletes taking 
statins.(23) Vulnerability to statin myopathy is increased in 
persons of Asian extraction, and also by female sex, advanced 
age, small body size and frailty. Chronic comorbidities such as 
diabetes, chronic kidney injury, hepatic dysfunction, untreated 
hypothyroidism and heavy alcohol intake are associated with a 
higher risk of myopathy. Acute perturbations such as drug 
abuse, acute infection, extensive surgery and major trauma may 
also be implicated.(19) Interactions between statins and other 
drugs, notably the inhibitors of cytochrome P450 CYP3A4 may 
result in the development of myopathy. This group of drugs 
includes, but is not limited to, the protease inhibitors, ciclosporin, 
amiodarone, the non-dihidropyridine calcium channel blockers 
(verapamil and diltiazem), digoxin, warfarin, the macrolide 
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antibiotics, the azole antifungal agents, the antidepressant 
nefazodone, the histamine H2 receptor blockers, omeprazole 
and grapefruit juice consumption in excess of 1 litre a day.(18) 
Because fluvastatin is metabolised by CYP2C9 and not by 
CYP3A4, it is free of this interaction. This difference in 
metabolism and the lower potency of fluvastatin are thought to 
account for the lower incidence of muscle symptoms 
encountered with its use.(13) The addition of a fibrate (especially 
gemfibrozil) to statin therapy increases the likelihood of 
myopathy by its action on a variety of mechanisms.(19) In 
addition, certain genetic polymorphisms (viz. SLCO1B1 and 
ABCG2) increase the predisposition to statin myopathy(24,25) 
by reducing the hepatic uptake of statin and exposing skeletal 
muscle to greater concentrations of the drug. 
Despite the frequent occurrence of statin-induced myopathy, 
the potential to reduce the risk of a clinical cardiovascular 
event (number needed to treat=27) is far greater than the 
potential for raising the CK >10X normal (number needed to 
harm [NNH]=3.400) or for rhabdomyolysis (NNH=7.428).(26) 
The significant difference in favour of continuing treatment 
emphasises the importance of exploring alternative strategies 
for controlling the cholesterol of patients who are intolerant of 
standard statin therapy.  
MANAGEMENT
No adequately powered trial has been carried out in patients 
with statin myopathy that has demonstrated a reliable method 
for managing the condition. Thus, in the absence of firm 
evidence, the following recommendations concerning the 
management of statin myopathy are based on the published 
opinions of experts in the field.
 ■ Review of the original indication for treatment: The 
emergence of muscle symptoms should occasion a re-
evaluation of the initial indication for treatment. Particularly 
in primary prevention in moderate risk patients, the need 
for statin therapy should be carefully reconsidered and the 
patient’s risk score reassessed. It is prudent not to admin-
ister statins to patients who are unlikely to derive significant 
benefit in the longer term. In such instances, statin treatment 
should be substituted with a lifestyle programme that 
incorporates exercise and a strict dietary regimen. On the 
other hand, because “lower is better,” in high risk patients 
requiring secondary prevention, it may be more appropriate 
to consider altering statin to a less aggressive regimen, even 
though the lipid target may not be fully met. 
 ■ Measure CK: In patients with CK levels 3-5X normal, it is 
safe to continue statin treatment provided that regular CK 
monitoring is undertaken thereafter. It is appropriate to 
discontinue the patient’s statin treatment when CK levels 
exceed 5X normal if there is no alternative explanation 
for the elevation e.g. recent strenuous or unaccustomed 
exercise.
 ■ Review of concomitant medication: The patient’s list of 
medications should be carefully reviewed to discover any 
potential for statin-drug interactions (Table 1). Whenever 
possible, the patient’s prescription should be adjusted to 
avoid these interactions.
 ■ Assess the patient’s exercise programme: Myopathic 
symptoms may be ameliorated by advising a reduction in 
exercise intensity in patients who exercise actively.
 ■ Consider a drug holiday: In patients with intolerable 
symptoms, temporary discontinuation of the statin for 2-3 
weeks should be proposed with a re-challenge following 
this break. It should then be possible to establish whether 
symptoms were improved or unaffected by withdrawing 
the statin, and whether symptoms return on re-challenge. 
TABLE 1: Factors increasing the risk of statin myopathy.
DHP=dihydropyridine 
Choice of statin Simvastatin in a dose >40mg daily
 More potent statins vs. less potent statins 
Diet  Grapefruit juice consumption in excess of 
1 litre a day
Strenuous exercise 
Demographic factors Asian extraction
 Female sex
 Advanced age
 Small body size
 Frailty
Chronic comorbidity Diabetes
 Chronic kidney injury
 Hepatic dysfunction
 Untreated hypothyroidism
 Heavy alcohol intake
Acute illness Acute infection
 Extensive surgery
 Major trauma
 Drug abuse
Concomitant medication Protease inhibitors
 Ciclosporin
 Amiodarone
  Non-DHP calcium channel blockers              
(verapamil and diltiazem)
 Digoxin
 Warfarin
 Macrolide antibiotics
 Azole antifungal agents
 Histamine H2 receptor blockers
 Omeprazole
 Fibates, especially gemfi brozil
Genetic polymorphism SLCO1B1
 ABCG2
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A Canadian group undertook a “trial of 1” to establish 
whether the muscle symptoms were truly related to statin 
use. Their method exposed the statin-intolerant patient to 
courses of the various statins, alternating with periods of 
placebo treatment, while continuously assessing the 
intensity of symptoms. In their experience, the majority of 
myopathic symptoms could not be related to statin 
treatment.(27) Statin treatment may be recommenced in 
patients whose symptoms do not improve after a period of 
withdrawal, dependent upon a risk-benefit evaluation.(10)
 ■ Consider altering the statin treatment: Existing statin 
treatment may be altered by:
• reducing the dose, 
•  changing the frequency of dosing to alternate days or to 
twice weekly when using a long-acting potent statin (high 
dose atorvastatin or rosuvastatin) or
•  switching to a less potent statin (fluvastatin, pravastatin or 
pitivastatin).
 ■ Combination treatment: A low dose of statin in com-
bination with ezetimibe may reduce the intensity of myalgia 
while effecting a significant reduction in LDL cholesterol. 
Recently the IMPROVE-IT outcome study demonstrated 
small, but significant, cardiovascular benefit when ezetimibe 
was added to simvastatin treatment (American Heart 
Association Annual Meeting, Chicago, 2014).
 ■ Non-statin monotherapy: Ezetimibe monotherapy may be 
tried if the patient remains intolerant of any statin treatment. 
A 10-15% fall in LDL cholesterol can be anticipated, 
significantly less than that achieved by statins. The bile acid 
sequestrants, such as cholestyramine and colesevelam, are 
not available in South Africa. Niacin or fibrate monotherapy 
is not recommended as these agents have little or no effect 
on LDL cholesterol and have not been shown to improve 
cardiovascular outcomes. 
 ■ Over-the-counter preparations: Red rice yeast extract and 
plant sterols effect small reductions in LDL cholesterol and 
may be tried as an alternative in the patient who is totally 
statin intolerant.(20)
 ■ Supplementation of Vitamin D in deficient patients: Non-
randomised studies have reported that muscle symptoms 
may resolve in Vitamin D deficient patients presenting 
with statin-induced myopathy after supplementation with 
Vitamin D 50 000 U weekly.(10)
 ■ Supplementation with coenzyme Q10: Although it has not 
been shown conclusively that CoQ10 improves statin 
myopathy, certain patients report an improvement in their 
muscle symptoms after adding CoQ10 200mg daily to their 
statin treatment. Whether the improvement represents 
individual responsiveness or placebo effect is not known. 
However, as CoQ10 has no known harmful effects, a trial 
of supplementation could be considered in patients 
refractory to other measures.(28)
 ■ Lipid-lowering agents undergoing development: The 
apolipoprotein B100 synthesis inhibitor mipomersein and 
the proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors such as evolucumab and alirocumab are both 
better tolerated than statins in statin-intolerant patients. 
However, as mipomersein use was associated with 
elevations in hepatic transaminase levels and steatosis, 
PCSK9 inhibition presently seems to be the more likely 
future substitute for statin treatment.(29,30)
CONCLUSION
Though myositis and rhabdomyolysis are extremely rare events 
during statin therapy, many patients will complain of myalgia 
when taking statin treatment. Although substantial experience 
suggests that much of the muscle ache encountered may not 
relate to statin treatment, the condition requires management 
nonetheless to ensure that patients with established athero-
sclerotic vascular disease, and those at high risk thereof, 
continue to receive treatment to reduce their LDL cholesterol. 
In many instances, it will be possible to continue statin therapy.
Disclosure: This review was initially undertaken at 
the request of DiscoveryHealth, which supported 
the author with a writing grant. 
The author gratefully acknowledges Mr Q. Barber of 
AstraZeneca for his assistance in accessing a number 
of the references quoted herein.
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